Revista de Saúde Pública (Aug 1986)
Importância clínica dos custos diretos hospitalares em pacientes com hipertensão arterial em tratamento num hospital universitário, Rio de Janeiro, Brasil The clinical importance of direct hospital costs in patients with arterial hypertension under treatment in an university hospital, Rio de Janeiro State, Brazil
Abstract
No ano de 1978 foram registrados no Hospital Universitário da Universidade Federal do Rio de Janeiro (HU-UFRJ), 5.262 pacientes moradores da XX Região Administrativa do Rio de Janeiro, Brasil. Quinhentos e três destes prontuários (9,6%) com idade >20 anos foram separados aleatoriamente e 483 destes possuiam registro de pressão arterial (PA) com 138 casos (28,6%) apresentando hipertensão arterial (HA) (PA >140/90 mmHg). Nos 96 hipertensos inicialmente analisados procedeu-se estudos dos custos diretos hospitalares com a avaliação, acompanhamento e tratamento desta população. A PA diastólica inicial destes casos estava assim distribuída: entre 90 e 104 mmHg - 67 casos (69,8%); entre 105 e 114 mmHg - 17 casos (17,7%); maior ou igual a 115 mmHg - 12 casos (12,5%). O período médio de acompanhamento destes grupos foi de 653 dias e somente 1/3 estava com PA controlada ( The authors analysed retrospectively 503 adult patients ( 140/90 mmHg). The 96 cases initially analysed were studied for the determination of the direct hospital costs involved in the evaluation, follow-up and treatment of such cases. The initial diastolic BP was distributed as follows: 90 to 104 mmHg-67 cases (69.8%); 105 to 114 mmHg-17 cases (17.7%); > 115 mmHg - 12 cases (12.5%). The mean follow-up period of this population was 653 days and at the last hospital visit only 1/3 had their BP under control ( < 140/90 mmHg). By 1982, 68.7% had abandoned their treatment. The total annual direct hospital costs per patient were $ 102.48 thus distributed: ambulatory consultations determined by the hypertension $ 33.44; emergency consultations $ 2.33; hospital admissions $ 29.92; laboratory tests $ 10.45; expenses with anti-hypertensive medications $ 26.34. The disease morbidity determined the great majority of the hospital consultations and admissions (64% of the costs). Disease morbidity also causes high indexes of temporary and permanent disability with major social costs. The analysis of the final costs determinants indicated the following measures for costs minimization: a) Development of programs within the health units with a view to better BP control and aiming at reducing the abandonment of treatment by the patients; b) Standardization of the laboratory evaluation and treatment, based on studies of cost-efficiency; c) The establishment of a hierarchy among the health units. The hypertensive patient must be treated in health units where indirect hospital costs do not much influence the final costs of hospital consultations and admissions.
Keywords